Clinical Trial

Assess the Safety and Tolerability of SNS851 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-10; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2026-03-18
Trial Details
NCT Number NCT07417124
Lead Sponsor Oneness Biotech Co., Ltd.
Conditions Metabolic Disease
Enrollment 52 participants
Start Date 2026-04-01
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-12